Orca Bio closed $250 million in financing to support the commercial launch of its T‑cell therapy for complications after allogeneic stem cell transplants. The capital will underwrite manufacturing scale‑up, regulatory submissions, and market entry activities. Orca positions the funding as critical to moving from clinical development to commercial availability for a cell therapy addressing high‑unmet‑need post‑transplant complications. The round underscores investor willingness to back later‑stage cell therapy commercialization, where manufacturing complexity and go‑to‑market execution determine success. Financing will also enable investment in supply chain, quality systems, and post‑market evidence generation needed for broad adoption. Orca’s cash and launch preparations place it among a cohort of cell therapy companies transitioning from trials to real‑world use, highlighting persistent investor conviction in cell and gene modalities when clinical benefit is established.